Dutch national guidelines for locally recurrent rectal cancer

After the introduction of total mesorectal excision (TME) and neoadjuvant treatment, the incidence of locally recurrent rectal cancer (LRRC) has decreased, but 6 –12 % of patients will still develop LRRC after primary rectal cancer.[1–5] At diagnosis, 40–60 % of patients present with distant metastases.[6–9] Detection of LRRC can be a challenge in itself, due to distorted anatomical planes and absence of the mesorectal fascia after primary rectal cancer surgery, the extra-luminal location of recurrences, and the presence of fibrosis or chronic inflammatory changes within the pelvis.

Source: Cancer Treatment Reviews - April 18, 2024 Category: Cancer & Oncology Authors: Floor Piqeur, Davy M.J. Creemers, Evi Banken, Li ën Coolen, Pieter J. Tanis, Monique Maas, Mark Roef, Corrie A.M. Marijnen, Irene E.G. van Hellemond, Joost Nederend, Harm J.T. Rutten, Heike M.U. Peulen, Jacobus W.A. Burger Source Type: research